ERCC1 and clinical resistance to platinum-based therapy.
Reed
Eddie
E
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, The Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA. duf7@cdc.gov
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D004720:Endonucleases / Q000235:genetics*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011110:Polymorphism, Genetic
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C071447:ERCC1 protein, human; D004720:Endonucleases; D005472:Fluorouracil